Literature DB >> 10085007

Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis.

A T Kamath1, C G Feng, M Macdonald, H Briscoe, W J Britton.   

Abstract

The development of more-effective antituberculosis vaccines would assist in the control of the global problem of infection with Mycobacterium tuberculosis. One recently devised vaccination strategy is immunization with DNA plasmids encoding individual microbial genes. Using the genes for the M. tuberculosis secreted proteins MPT64 (23 kDa), Ag85B (30 kDa), and ESAT-6 (6 kDa) as candidate antigens, DNA vaccines were prepared and tested for immunogenicity and protective efficacy in a murine model of aerosolized tuberculosis (TB). Intramuscular immunization with DNA-64 or DNA-85B resulted in the activation of CD4(+) T cells, which produce gamma interferon (IFN-gamma), and high titers of specific immunoglobulin G antibodies. Further, DNA-64 induced major histocompatibility complex class I-restricted CD8(+) cytotoxic T cells. The addition of a eukaryotic leader sequence to mpt64 did not significantly increase the T-cell or antibody response. Each of the three DNA vectors stimulated a significant reduction in the level of M. tuberculosis infection in the lungs of mice challenged 4 weeks after immunization, but not to the levels resulting after immunization with Mycobacterium bovis BCG. The vaccines showed a consistent hierarchy of protection, with the most effective being Ag85B, followed by ESAT-6 and then MPT64. Coimmunization with the three vectors resulted in a greater degree of protection than that induced by any single vector. This protective efficacy was associated with the emergence of IFN-gamma-secreting T cells earlier than in infected animals immunized with a control vector. The efficacy of these DNA vaccines suggests that multisubunit vaccination may contribute to future vaccine strategies against TB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10085007      PMCID: PMC96517          DOI: 10.1128/IAI.67.4.1702-1707.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Identification of immunodominant antigens during infection with Mycobacterium tuberculosis.

Authors:  P Andersen; D Askgaard; A Gottschau; J Bennedsen; S Nagai; I Heron
Journal:  Scand J Immunol       Date:  1992-12       Impact factor: 3.487

2.  The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis.

Authors:  I M Orme
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

3.  In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines.

Authors:  R C Hedstrom; D L Doolan; R Wang; A Kumar; J B Sacci; M J Gardner; J C Aguiar; Y Charoenvit; M Sedegah; J A Tine; M Margalith; P Hobart; S L Hoffman
Journal:  Int J Mol Med       Date:  1998-07       Impact factor: 4.101

4.  Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction.

Authors:  J S Boyle; J L Brady; A M Lew
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

5.  Identification of potential CD8+ T-cell epitopes of the 19 kDa and AhpC proteins from Mycobacterium tuberculosis. No evidence for CD8+ T-cell priming against the identified peptides after DNA-vaccination of mice.

Authors:  K J Erb; J Kirman; L Woodfield; T Wilson; D M Collins; J D Watson; G LeGros
Journal:  Vaccine       Date:  1998-04       Impact factor: 3.641

6.  Introduction of soluble protein into the class I pathway of antigen processing and presentation.

Authors:  M W Moore; F R Carbone; M J Bevan
Journal:  Cell       Date:  1988-09-09       Impact factor: 41.582

7.  Cloning, sequence determination, and expression of a 32-kilodalton-protein gene of Mycobacterium tuberculosis.

Authors:  M Borremans; L de Wit; G Volckaert; J Ooms; J de Bruyn; K Huygen; J P van Vooren; M Stelandre; R Verhofstadt; J Content
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

8.  Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis.

Authors:  A Lalvani; R Brookes; R J Wilkinson; A S Malin; A A Pathan; P Andersen; H Dockrell; G Pasvol; A V Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

Review 9.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

Review 10.  T cell response to Mycobacterium tuberculosis.

Authors:  I M Orme; P Andersen; W H Boom
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

View more
  90 in total

1.  Mycobacterium tuberculosis-secreted protein antigens: immunogenicity in baboons.

Authors:  K Pehler; K M Brasky; T M Butler; R Attanasio
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection.

Authors:  E Martin; J A Triccas; A T Kamath; N Winter; W J Britton
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

3.  Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.

Authors:  C G Feng; U Palendira; C Demangel; J M Spratt; A S Malin; W J Britton
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 5.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

6.  Mutations including IS6110 insertion in the gene encoding the MPB64 protein of Capilia TB-negative Mycobacterium tuberculosis isolates.

Authors:  Kazue Hirano; Akio Aono; Mitsuyoshi Takahashi; Chiyoji Abe
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

7.  Protein-protein interactions of proteins from the ESAT-6 family of Mycobacterium tuberculosis.

Authors:  Limei Meng Okkels; Peter Andersen
Journal:  J Bacteriol       Date:  2004-04       Impact factor: 3.490

8.  Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.

Authors:  D P Fonseca; B Benaissa-Trouw; M van Engelen; C A Kraaijeveld; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

9.  Bovine NK cells can produce gamma interferon in response to the secreted mycobacterial proteins ESAT-6 and MPP14 but not in response to MPB70.

Authors:  Ingrid Olsen; Preben Boysen; Siri Kulberg; Jayne C Hope; Gregers Jungersen; Anne K Storset
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

10.  A novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection.

Authors:  Hongmei Kong; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.